Cost of cardiovascular disease prevention: towards economic evaluations in prevention programs.
作者信息
Santos João Vasco, Vandenberghe Désirée, Lobo Mariana, Freitas Alberto
机构信息
Public Health Unit, ACES Grande Porto VIII - Espinho/Gaia, ARS Norte, Portugal.
MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Portugal.
出版信息
Ann Transl Med. 2020 Apr;8(7):512. doi: 10.21037/atm.2020.01.20.
Abstract
摘要
相似文献
1
Cost of cardiovascular disease prevention: towards economic evaluations in prevention programs.
Ann Transl Med. 2020 Apr;8(7):512. doi: 10.21037/atm.2020.01.20.
2
Economic evaluations of smoking cessation and relapse prevention programs for pregnant women: a systematic review.
Value Health. 2008 Mar-Apr;11(2):180-90. doi: 10.1111/j.1524-4733.2007.00239.x. Epub 2007 Sep 13.
3
Economic Evaluations of Falls Prevention Programs for Older Adults: A Systematic Review.
J Am Geriatr Soc. 2018 Nov;66(11):2197-2204. doi: 10.1111/jgs.15578. Epub 2018 Oct 16.
4
CARDIOVASCULAR SCREENING OF YOUNG ATHLETES: A REVIEW OF ECONOMIC EVALUATIONS.
Int J Technol Assess Health Care. 2017 Jan;33(1):76-83. doi: 10.1017/S0266462317000162. Epub 2017 Apr 24.
5
An Economic Evaluation of a Comprehensive School-Based Caries Prevention Program.
JDR Clin Trans Res. 2019 Oct;4(4):378-387. doi: 10.1177/2380084419837587. Epub 2019 Apr 22.
6
Economic evaluations of screening programs: a review of methods and results.
Clin Chim Acta. 2002 Jan;315(1-2):31-40. doi: 10.1016/s0009-8981(01)00718-5.
7
Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.
Acta Cardiol. 2009 Feb;64(1):1-10. doi: 10.2143/AC.64.1.2034354.
8
Economic evaluations of public health implementation-interventions: a systematic review and guideline for practice.
Public Health. 2019 Apr;169:101-113. doi: 10.1016/j.puhe.2019.01.012. Epub 2019 Mar 13.
9
Economic evaluations and their use in infection prevention and control: a narrative review.
Antimicrob Resist Infect Control. 2018 Feb 27;7:31. doi: 10.1186/s13756-018-0327-z. eCollection 2018.
10
Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of Interventions.
Value Health. 2019 Nov;22(11):1329-1344. doi: 10.1016/j.jval.2019.06.011. Epub 2019 Sep 10.
引用本文的文献
1
Direct economic burden of acute coronary syndromes in the Portuguese National Health Service-facts and trends between 2002 and 2022.
Front Public Health. 2025 Mar 18;13:1433307. doi: 10.3389/fpubh.2025.1433307. eCollection 2025.
2
Machine learning-based risk prediction for major adverse cardiovascular events in a Brazilian hospital: Development, external validation, and interpretability.
PLoS One. 2024 Oct 11;19(10):e0311719. doi: 10.1371/journal.pone.0311719. eCollection 2024.
3
Optimizing cardiovascular disease mortality prediction: a super learner approach in the tehran lipid and glucose study.
BMC Med Inform Decis Mak. 2024 Apr 16;24(1):97. doi: 10.1186/s12911-024-02489-0.
4
Postprandial Plasma Glucose Measured from Blood Taken between 4 and 7.9 h Is Positively Associated with Mortality from Hypertension and Cardiovascular Disease.
J Cardiovasc Dev Dis. 2024 Feb 4;11(2):53. doi: 10.3390/jcdd11020053.
5
Optimizing Cardiac Wireless Implant Communication: A Feasibility Study on Selecting the Frequency and Matching Medium.
Sensors (Basel). 2023 Mar 24;23(7):3411. doi: 10.3390/s23073411.
6
Why and How Should We Assess the Cardiovascular Risk in Patients with Juvenile Idiopathic Arthritis? A Single-Centre Experience with Carotid Intima-Media Measurements.
Children (Basel). 2023 Feb 22;10(3):422. doi: 10.3390/children10030422.
7
Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study.
J Health Econ Outcomes Res. 2022 Nov 22;9(2):134-146. doi: 10.36469/001c.39768. eCollection 2022.
8
Reduction in medical costs for cardiovascular diseases through innovative health awareness projects in a rural area in Japan.
PLoS One. 2022 Nov 16;17(11):e0277600. doi: 10.1371/journal.pone.0277600. eCollection 2022.
9
Cerebrovascular development: mechanisms and experimental approaches.
Cell Mol Life Sci. 2021 May;78(9):4377-4398. doi: 10.1007/s00018-021-03790-1. Epub 2021 Mar 10.
本文引用的文献
1
The financial burden of non-communicable diseases in the European Union: a systematic review.
Eur J Public Health. 2020 Aug 1;30(4):833-839. doi: 10.1093/eurpub/ckz073.
2
5-year versus risk-category-specific screening intervals for cardiovascular disease prevention: a cohort study.
Lancet Public Health. 2019 Apr;4(4):e189-e199. doi: 10.1016/S2468-2667(19)30023-4.
3
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017.
Lancet. 2018 Nov 10;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7. Epub 2018 Nov 8.
4
Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
Lancet. 2018 Nov 10;392(10159):1859-1922. doi: 10.1016/S0140-6736(18)32335-3.
5
Multimorbidity Trends in United States Adults, 1988-2014.
J Am Board Fam Med. 2018 Jul-Aug;31(4):503-513. doi: 10.3122/jabfm.2018.04.180008.
6
Primary and secondary prevention interventions for cardiovascular disease in low-income and middle-income countries: a systematic review of economic evaluations.
Cost Eff Resour Alloc. 2018 Jun 14;16:22. doi: 10.1186/s12962-018-0108-9. eCollection 2018.
7
A cost-effectiveness analysis of a community based CVD program in Sweden based on a retrospective register cohort.
BMC Public Health. 2018 Apr 4;18(1):452. doi: 10.1186/s12889-018-5339-3.
8
10-Year Resource Utilization and Costs for Cardiovascular Care.
J Am Coll Cardiol. 2018 Mar 13;71(10):1078-1089. doi: 10.1016/j.jacc.2017.12.064.
9
The global impact of non-communicable diseases on healthcare spending and national income: a systematic review.
Eur J Epidemiol. 2015 Apr;30(4):251-77. doi: 10.1007/s10654-014-9984-2. Epub 2015 Jan 18.
10
Who needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines.
Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):25-32. doi: 10.1161/CIRCOUTCOMES.113.000397. Epub 2014 Jan 14.
Zotero 插件